Humacyte Inc is trading at $0.96, down 6.7% today as investors continue to take profits following a recent public offering. - The company recently completed a $50 million public offering of shares priced at $1.05 per share, which closed around June 12, 2026. - This offering followed a significant rally fueled by positive Phase 3 dialysis data announced on June 10, 2026, and bullish analyst actions from Benchmark, BTIG, and H.C. Wainwright. - The current pullback suggests a cooling of post-trial momentum, likely influenced by the recent dilution from the share offering.